ES2058892T3 - Uso de omeprazol como agente antimicrobiano. - Google Patents

Uso de omeprazol como agente antimicrobiano.

Info

Publication number
ES2058892T3
ES2058892T3 ES90902854T ES90902854T ES2058892T3 ES 2058892 T3 ES2058892 T3 ES 2058892T3 ES 90902854 T ES90902854 T ES 90902854T ES 90902854 T ES90902854 T ES 90902854T ES 2058892 T3 ES2058892 T3 ES 2058892T3
Authority
ES
Spain
Prior art keywords
omeprazole
antimicrobial agent
metoxi
benzoimidiazole
campilobacter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90902854T
Other languages
English (en)
Inventor
Masaaki - - - Nishi-Iwat Tomoi
Yoshifumi - Oaza-Nakasoi Ikeda
Yoshiko - Wakazono-Cho Yokota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2058892(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hassle AB filed Critical Hassle AB
Application granted granted Critical
Publication of ES2058892T3 publication Critical patent/ES2058892T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE 5-METOXI-2-[[(4-METOXI-3,5-DIMETIL-2-PIRIDINILO) METILO]-1H-BENZOIMIDIAZOL O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE EL EN EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS, ESPECIALES EN AQUELLAS CAUSADAS POR "CAMPILOBACTER PILORI".
ES90902854T 1989-02-09 1990-02-02 Uso de omeprazol como agente antimicrobiano. Expired - Lifetime ES2058892T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1030311A JP2694361B2 (ja) 1989-02-09 1989-02-09 抗菌剤

Publications (1)

Publication Number Publication Date
ES2058892T3 true ES2058892T3 (es) 1994-11-01

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90902854T Expired - Lifetime ES2058892T3 (es) 1989-02-09 1990-02-02 Uso de omeprazol como agente antimicrobiano.

Country Status (19)

Country Link
US (1) US5093342A (es)
EP (1) EP0414847B1 (es)
JP (1) JP2694361B2 (es)
KR (1) KR0140236B1 (es)
AT (1) ATE94063T1 (es)
AU (1) AU626641B2 (es)
CA (1) CA2025668C (es)
CY (1) CY1909A (es)
DE (1) DE69003207T2 (es)
DK (1) DK0414847T3 (es)
ES (1) ES2058892T3 (es)
HK (1) HK52196A (es)
HU (1) HU205253B (es)
IE (1) IE65814B1 (es)
IL (1) IL93263A0 (es)
LV (1) LV10577B (es)
MY (1) MY111737A (es)
PH (1) PH26787A (es)
WO (1) WO1990009175A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382489B1 (en) * 1989-02-10 1994-11-17 Takeda Chemical Industries, Ltd. Use of benzimidazole derivatives as antibacterial agents
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
DK0548103T3 (da) * 1990-09-14 2002-04-02 Byk Gulden Lomberg Chem Fab Anvendelse af pyridylmethylsulfinyl-1H-benzimidazolderivater til behandling af sygdomme, der er fremkaldt af Helicobacter-bakterier
IS3990A (is) * 1992-04-24 1993-10-25 Ab Astra Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
WO1996024341A1 (en) * 1995-02-07 1996-08-15 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
EE04576B1 (et) * 1997-12-08 2006-02-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
ATE271555T1 (de) 1998-01-14 2004-08-15 Uab Research Foundation Verfahren zur herstellung und screening von inhibitoren des bakteriellen nad synthetase enzyms, verbindungen daraus und methoden zur behandlung bakterieller und mikrobieller infektionen mit diesen inhibitoren
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
ES2374730T3 (es) 2006-03-10 2012-02-21 Arigen Pharmaceuticals, Inc. Nuevo derivado de piridina que tiene actividad contra helicobacter pylori.
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
PL2103608T3 (pl) 2006-12-18 2013-02-28 Link Genomics Inc Środek do eradykacji Helicobacter pylori mający działanie hamujące na sekrecję kwasu żołądkowego
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
RU2484089C1 (ru) 2009-04-09 2013-06-10 Ариджен Фармасьютикалз, Инк. Тиопроизводное пиридина и фармацевтическая композиция, которая его содержит и имеет способность действовать против helicobacter pylori
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US8722026B2 (en) * 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) * 2014-08-27 2016-06-08 경북대학교 산학협력단 오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
WO1989003830A1 (en) * 1987-10-30 1989-05-05 Aktiebolaget Hässle 2-pyridinylmethyl (sulfinyl or thio)benzimidazoles for treatment of diseases related to bone loss

Also Published As

Publication number Publication date
KR910700048A (ko) 1991-03-13
WO1990009175A1 (en) 1990-08-23
DE69003207D1 (de) 1993-10-14
AU5038190A (en) 1990-09-05
AU626641B2 (en) 1992-08-06
LV10577B (en) 1995-10-20
IL93263A0 (en) 1990-11-29
DE69003207T2 (de) 1994-02-03
MY111737A (en) 2000-12-30
LV10577A (lv) 1995-04-20
HUT54890A (en) 1991-04-29
EP0414847B1 (en) 1993-09-08
US5093342A (en) 1992-03-03
CA2025668C (en) 1998-09-15
JP2694361B2 (ja) 1997-12-24
PH26787A (en) 1992-10-13
EP0414847A1 (en) 1991-03-06
IE900418L (en) 1990-08-09
HU205253B (en) 1992-04-28
HK52196A (en) 1996-03-29
CA2025668A1 (en) 1990-08-10
ATE94063T1 (de) 1993-09-15
HU901539D0 (en) 1991-02-28
KR0140236B1 (ko) 1998-06-01
DK0414847T3 (da) 1993-12-13
JPH02209809A (ja) 1990-08-21
IE65814B1 (en) 1995-11-15
CY1909A (en) 1990-02-02

Similar Documents

Publication Publication Date Title
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
NO932650D0 (no) Forbedringer vedroerende benzotiofener
ES2159591T3 (es) Composicion de liberacion controlada.
GEP19981482B (en) Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B
TW234691B (es)
ES2130114T3 (es) 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepinas y su uso en la prevencion o tratamiento de infeccion por hiv.
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
CL2008003939A1 (es) Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00).
DE59204364D1 (de) Zahnärztlicher Patientenstuhl.
NO911429D0 (no) Stoffbehandling.
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
ITRM930488A0 (it) Composizione detergente per la cura del corpo.
IT1318365B1 (it) Dispositivo di protezione per l'ago per siringa ad uso medicale.
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU3401093A (en) Therapeutic agent for threatened abortion
NO911430D0 (no) Stoffbehandlingsmetode.
DE68906245T2 (de) Therapeutisches Mittel gegen Aids.
ATE196631T1 (de) Xamonelin-tartrat
MX9203221A (es) Compuesto farmacologicamente activo, preparacion y empleo.
SE9602262D0 (sv) New use of derivatives of cystine
NO922437D0 (no) Terapeutisk aktive fluorsubstituerte benzimidazoler, fremgangsmaate for deres fremstilling samt deres anvendelse
NO900731D0 (no) Boelgelengde-spesifikke cytotoksiske midler.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 414847

Country of ref document: ES